

$$\begin{aligned} & \bullet \quad 1 \\ & 2 \end{aligned}$$

» (0108 009464)
" - ,
,
" (0108 04716).

[19].

1 5% 400,0
- 1 10 , 2
- 3 30-40 .

- « »
726 3.11.2006 . -

- /5324/01/01) [4].

- [4].

[4, 7, 14].

, (,) , ;
 , , (') , , -
 , , -
 , -
 , -
 [14]. « » - ;
 , , -
 , (1.1.1.27) -
 [4, 17]. (. 1). -
 (-
 '), (, ' -
) (/ -
), (-
 -), [3].
 1, -
 •- , -
 , , -
 , (2,72±0,08) / - ,
 1,3
 (2,68±0,09) / - ,
 1,27 (<0,01). -
 (1.1.1.27)
 [12],
 Sevela Tovarek [8]. (. 1).
 , L- (, " " () 1+2
) , () ,
 , 1,97
 [13]. (39,3±1,5)% (<0,001)
 1,53
 (1,07±0,04)
 [12]. (/ - (<0,001). -
 1.1.1.27) 1+2 -
 -3
 1,9 ((41,7±1,3)%;
 [3]. <0,001) -
 1,46 ((1,12±0,06) /
 ; <0,001).
 Intel Pentium III 800 " "
 - 3
 Microsoft Office 97, Microsoft Excel Stadia 6.1 / prof ,
 Statistica, 2,9 (<0,001)
 2,8
 [11]. (<0,001);
 3
 (1,33±0,03) / - ,
 3,76 (<0,001); -
 , , ,
 (1,24±0,06) / - ,
 3,56 (<0,001).
 " " (-
 -) - 4+5 -
 , 3-4 -
 2,84
 (0,37±0,03) / -

	(±)		
	(=32)	(=32)	
(^ ^ / -)	2,72±0,08 <0,01	2,68±0,09 1<0,01	>0,05
	(2,11±0,05) / -		
1+2 (%) (/ -)	39,3±1,5 ,<0,001	41,7±1,3 1<0,001	>0,05
	(77,5±2,3) %		
	1,07±0,04 <0,001	1,12±0,06 1<0,001	>0,05
	(1,64±0,05) / -		
3 (%) (/ -)	47,1±2,6 ,<0,001	45,1±2,8 ,<0,001	>0,05
	(16,2±1,1) %		
	1,28±0,03 1<0,001	1,21±0,06 1<0,001	>0,05
	(0,34±0,02) / -		
4+5 (%) (/ -)	13,6±1,2 <0,001	13,1±1,8 1<0,01	>0,05
	(6,3±0,4) %		
	0,37±0,03 1<0,001	0,31±0,04 1<0,001	>0,05
	(0,13±0,01) / -		

: 1-2 ; 2

(<0,001) - 2,7 ,
(0,35±0,04) / - (<0,001).
()
,
,
2,
-
,
,
,
29 (90,6%) -
-
(1,96-2,26) / - ,
,
(2,47±0,09) / - (>0,05).
-
-
" " 1+2,
14 (43,7%) , 2,1 -
2. 1,33 -
, 2, , - 1,2 " "
3 ,
,
- 1,85 ,
- 2,2 (0,73±0,06) / -
" () 4+5

() () , -
 « » 4+5 " " 3 -
 « » 1+2. -
 , -

I.O. Shapovalova, T.P. Garnik

INFLUENCE METABOLIC ACTIVE PREPARATION GEPADIF TO ACTIVITY OF LACTATEDEHYDROGENASE AT BLOOD SERUM AND IT IZOENZYMES SPECTRUM OF THE PATIENTS WITH THE CHRONIC TOXIC HEPATITIS COMBINED WITH CHRONIC UNCALCULOSIS CHOLECYSTITIS ON BACKGROUND OF OBESITY

Key words: chronic toxic hepatitis, chronic uncalculosis cholecystitis, obesity, lactatedehydrogenase, gepadif, treatment

Influence of gepadif on activity of lactatedehydrogenase (LDG) at blood serum and it izoenzymes spectrum at patients with chronic toxic hepatitis (CTH) combined with chronic uncalculosis cholecystitis (CUC) on background of obesity (Ob). It is set that to beginning of treatment at the patients with CTH combined with CUC on on background of Ob the increase of general activity of serum LDG, increase of maintenance "intermediate" LDG3 was marked and sums of cathode "anaerobic" LDG4+5 in the blood serum and at the same time substantial diminishing of level of anodal "aerobic" LDG1+2. At application of gepadif in the complex of treatment of patients CTH combined with CUC on on background of Ob, marked normalization of general activity serum LDG and in most cases improvement of izoenzymes spectrum of LDG which testifies to nosotropic validity of the use of gepadif at treatment of the with patients CTH combined with CUC on on background of Ob.

: 616.61-002.3-036.12-08:616.379-008.64

- 4
- 4
-

« »

2

(), -
 2 () , [3]. -
 , « -
 » [1, 2, , . -
 10]. -
 35%, 7-8 , -
 [5, 9]. -
 . -
 . -
 . -
 . -
 « » -
 , 2 . -
 . -
 . -
 110 -
 2 . -
 12(11%), -
 98(89%) 45-80 . -